• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱过度活动症患者夜尿症的年龄相关发病机制。

Age related pathogenesis of nocturia in patients with overactive bladder.

作者信息

Weiss Jeffrey P, Blaivas Jerry G, Jones Mark, Wang Joseph T, Guan Zhonghong

机构信息

Weill Cornell Medical Center, New York, New York 10021, USA.

出版信息

J Urol. 2007 Aug;178(2):548-51; discussion 551. doi: 10.1016/j.juro.2007.03.117. Epub 2007 Jun 14.

DOI:10.1016/j.juro.2007.03.117
PMID:17570424
Abstract

PURPOSE

Nocturia is caused by increased nocturnal urine output (nocturnal polyuria) and/or diminished nocturnal bladder capacity. We retrospectively evaluated the causes of nocturia in patients with overactive bladder and nocturia.

MATERIALS AND METHODS

A total of 850 patients (18 years or older) with symptoms of overactive bladder (8 or more micturitions per 24 hours and urgency or urgency urinary incontinence) and nocturia (mean of 2.5 or more episodes per night) were enrolled in a 12-week study of tolterodine ER (4 mg QD) vs placebo. Of this total 845 patients (417 men and 428 women) completed 7-day bladder diaries. Patients were stratified post hoc by sex and age groups (less than 50, 50 to 70, more than 70 years). Indices of nocturnal urine production (nocturia index, nocturnal polyuria index and nocturnal bladder capacity index) were compared using ANOVA (alpha level 0.05). Higher nocturia index and nocturnal polyuria index values suggest that nocturia occurs because of nocturnal urine overproduction. Higher nocturnal bladder capacity index values suggest that nocturia occurs because of decreased nocturnal bladder capacity.

RESULTS

There were no statistically significant gender or age related differences in baseline nocturnal micturitions. Nocturia index increased significantly with age (p <0.0001), and values were significantly higher among men than women for all age groups (p = 0.0064). Nocturnal polyuria index increased significantly with age (p <0.0001) and there were no gender differences. For nocturnal bladder capacity index there was a significant decrease with advancing age among men (1.75 greater than 1.16 greater than 0.90) and women (1.53 greater than 1.42 greater than 1.08, P(interaction) = 0.0148).

CONCLUSIONS

In younger patients with overactive bladder, decreased nocturnal bladder capacity has a greater role in the pathogenesis of nocturia symptoms, whereas in older patients increased nocturnal urine output has a greater role.

摘要

目的

夜尿症是由夜间尿量增加(夜间多尿)和/或夜间膀胱容量减小引起的。我们回顾性评估了膀胱过度活动症合并夜尿症患者夜尿症的病因。

材料与方法

共有850例年龄在18岁及以上、有膀胱过度活动症症状(每24小时排尿8次或更多,伴有尿急或急迫性尿失禁)和夜尿症(平均每晚发作2.5次或更多)的患者参加了一项为期12周的托特罗定缓释片(4毫克,每日一次)与安慰剂对比研究。这850例患者中,845例(417例男性和428例女性)完成了7天的膀胱日记。患者事后按性别和年龄组(小于50岁、50至70岁、大于70岁)进行分层。使用方差分析(α水平0.05)比较夜间尿量指标(夜尿指数、夜间多尿指数和夜间膀胱容量指数)。较高的夜尿指数和夜间多尿指数值表明夜尿症是由于夜间尿量过多所致。较高的夜间膀胱容量指数值表明夜尿症是由于夜间膀胱容量减小所致。

结果

基线夜间排尿次数在性别或年龄方面无统计学显著差异。夜尿指数随年龄显著增加(p<0.0001),且在所有年龄组中男性的值均显著高于女性(p = 0.0064)。夜间多尿指数随年龄显著增加(p<0.0001),且无性别差异。对于夜间膀胱容量指数,男性(1.75>1.16>0.90)和女性(1.53>1.42>1.08,P(交互作用)= 0.0148)均随年龄增长显著降低。

结论

在年轻的膀胱过度活动症患者中,夜间膀胱容量减小在夜尿症症状的发病机制中起更大作用,而在老年患者中,夜间尿量增加起更大作用。

相似文献

1
Age related pathogenesis of nocturia in patients with overactive bladder.膀胱过度活动症患者夜尿症的年龄相关发病机制。
J Urol. 2007 Aug;178(2):548-51; discussion 551. doi: 10.1016/j.juro.2007.03.117. Epub 2007 Jun 14.
2
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.托特罗定治疗可改善接受α受体阻滞剂治疗的男性中提示膀胱过度活动症的储尿期症状。
Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24.
3
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.托特罗定缓释剂可改善患有膀胱过度活动症和夜尿症男性的膀胱过度活动症症状。
Urology. 2006 Aug;68(2):328-32. doi: 10.1016/j.urology.2006.03.006.
4
Pathophysiological aspects of nocturia in a danish population of men and women age 60 to 80 years.丹麦60至80岁男性和女性夜尿症的病理生理方面
J Urol. 2007 Aug;178(2):552-7. doi: 10.1016/j.juro.2007.03.141. Epub 2007 Jun 14.
5
Comparison of fesoterodine and tolterodine in patients with overactive bladder.非索罗定与托特罗定治疗膀胱过度活动症患者的比较。
BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.
6
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.索利那新在曾接受4毫克托特罗定缓释制剂治疗的患者中的疗效:一项为期12周的多中心、开放标签、灵活剂量研究的结果。
Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.
7
A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.一项随机双盲安慰剂对照多中心研究,旨在探讨坦索罗辛和托特罗定对膀胱过度活动症女性患者的疗效和安全性。
BJU Int. 2007 Oct;100(4):840-5. doi: 10.1111/j.1464-410X.2007.07162.x.
8
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.非索罗定与托特罗定缓释片治疗膀胱过度活动症的疗效比较:男女患者的疗效比较。
BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.
9
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.托特罗定缓释制剂对患有膀胱过度活动症的尿失禁和非尿失禁患者均有效。
Urology. 2008 Sep;72(3):488-93. doi: 10.1016/j.urology.2008.05.019. Epub 2008 Jul 17.
10
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.在患有下尿路症状和膀胱过度活动症的男性中,使用或不使用坦索罗辛的缓释托特罗定:对通过国际前列腺症状评分评估的泌尿症状的影响。
BJU Int. 2008 Nov;102(9):1133-9. doi: 10.1111/j.1464-410X.2008.07761.x. Epub 2008 May 26.

引用本文的文献

1
Clinical manifestations of interstitial cystitis and bladder pain syndrome: Analysis of a patient registry in Japan.间质性膀胱炎和膀胱疼痛综合征的临床表现:日本一项患者登记研究分析
Int J Urol. 2025 Jan;32(1):103-109. doi: 10.1111/iju.15603. Epub 2024 Oct 18.
2
A positive association between the prevalence of circadian syndrome and overactive bladder in United States adults.美国成年人昼夜节律紊乱综合征与膀胱过度活动症之间呈正相关。
Front Public Health. 2023 Aug 10;11:1137191. doi: 10.3389/fpubh.2023.1137191. eCollection 2023.
3
A Comprehensive Community-Based Prevalence Study on Nocturia in Hong Kong Male Adults.
香港成年男性夜间多尿症的综合社区患病率研究。
Int J Environ Res Public Health. 2021 Aug 29;18(17):9112. doi: 10.3390/ijerph18179112.
4
Dietary considerations in the evaluation and management of nocturia.夜尿症评估与管理中的饮食考量
F1000Res. 2020 Mar 5;9. doi: 10.12688/f1000research.21466.1. eCollection 2020.
5
Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder.米拉贝隆25毫克单药治疗以夜尿为主的膀胱过度敏感患者的疗效
Tzu Chi Med J. 2019 Apr 2;32(1):30-35. doi: 10.4103/tcmj.tcmj_226_18. eCollection 2020 Jan-Mar.
6
The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis.美国卫生保健系统和社会的夜间多尿症经济负担:国家健康和营养调查分析。
J Manag Care Spec Pharm. 2019 Dec;25(12):1398-1408. doi: 10.18553/jmcp.2019.19191. Epub 2019 Sep 30.
7
Association between the Urinary Bladder Volume and the Incidence of "De Novo" Overactive Bladder in Patients with Stress Urinary Incontinence Subjected to Sling Surgeries or Burch Procedure.膀胱容量与吊带手术或膀胱颈悬吊术后压力性尿失禁患者新发“特发性”膀胱过度活动症的关系。
Biomed Res Int. 2019 Feb 12;2019:9515242. doi: 10.1155/2019/9515242. eCollection 2019.
8
Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality.索利那新日间或夜间给药对伴有夜尿症的膀胱过度活动症的影响:对夜尿症和睡眠质量的影响
J Korean Med Sci. 2017 Sep;32(9):1491-1495. doi: 10.3346/jkms.2017.32.9.1491.
9
Practical points in the medical treatment of overactive bladder and nocturia in the elderly.老年人膀胱过度活动症和夜尿症医学治疗中的实用要点。
Tzu Chi Med J. 2016 Jan-Mar;28(1):1-5. doi: 10.1016/j.tcmj.2015.12.003. Epub 2016 Jan 25.
10
Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.德国、瑞典和英国因夜尿症产生的年度直接和间接成本。
Eur J Health Econ. 2017 Jul;18(6):761-771. doi: 10.1007/s10198-016-0826-x. Epub 2016 Sep 27.